genengnews
Influenza A virus (IAV) utilizes a multivalent binding strategy to the host cell, binding its trimeric spike protein hemagglutinin (HA) to sialic acid present on the cellular membrane.
Watch Now
Multiple challenges exist in bioanalytical assay development, from antibody generation to quality control. A researcher must first decide if an analyte will be measured in all or only certain desired forms, identify the sample types or matrices in which it will be measured, and identify the appropriate sensitivity and specificity required of their assay. The role of the antibody (i.e., capture, detection, or reagent), as well as its required format, must also be identified. Lastly, the generated antibodies must be characterized and validated in terms of supply continuity, robustness, reproducibility, and stability. In this webinar, Dr. Royle addresses these challenges and discusses specific antibody generation using Bio-Rad’s HuCAL technology, format flexibility offered by SpyTag technology, antibody formats for different bioanalytical assays, and quality and performance of Bio-Rad antibody products.
Watch Now
The dynamics of tumor and immune responses associated with immune checkpoint blockade are unique and complex. Despite the initial successes of immunotherapy, a low objective response rate due to resistance is still the main challenge in solid tumors, particularly advanced-stage lung cancer.
Watch Now
T cell receptors (TCRs) allow the adaptive immune system to recognize and respond to a vast array of threats, ranging from viruses to malignant cells. Single-cell sequencing has made it possible to explore an individual’s TCR repertoire and quantify changes due to an immune response. To fully unlock the great potential of these measurements we need to know which antigens each TCR binds.
Watch Now